BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 15947082)

  • 1. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR; Koralnik IJ
    N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
    [No Abstract]   [Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK; Tyler KL
    N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
    N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients at risk.
    Drazen JM
    N Engl J Med; 2005 Jul; 353(4):417. PubMed ID: 15947081
    [No Abstract]   [Full Text] [Related]  

  • 5. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B; Sandrock A; Panzara MA
    N Engl J Med; 2005 Jul; 353(4):432-3. PubMed ID: 15947083
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
    Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
    N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab for relapsing multiple sclerosis.
    Meyer MA
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract]   [Full Text] [Related]  

  • 10. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C; Adams O; Kieseier BC
    N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab for relapsing multiple sclerosis.
    Tenser RB
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract]   [Full Text] [Related]  

  • 13. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective treatment of multiple sclerosis.
    Ropper AH
    N Engl J Med; 2006 Mar; 354(9):965-7. PubMed ID: 16510751
    [No Abstract]   [Full Text] [Related]  

  • 15. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C; Smolianov V; Dehmel T; Andrée M; Hengel H; Zohren F; Arendt G; Wiendl H; Haas R; Hartung HP; Adams O; Kieseier BC
    Mult Scler; 2011 Feb; 17(2):151-6. PubMed ID: 21078695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC; Masjuan J; Villar LM
    N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract]   [Full Text] [Related]  

  • 17. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT; Bourdette D
    Neurology; 2011 May; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs; natalizumab].
    van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.